Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - paracetamol, quantity: 500 mg; phenylephrine hydrochloride, quantity: 5 mg - tablet, uncoated - excipient ingredients: sodium metabisulfite; purified water; quinoline yellow; stearic acid; maize starch; disodium edetate; pregelatinised maize starch; magnesium stearate; microcrystalline cellulose - for the temporary relief of symptoms of cold and flu.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - ibuprofen -

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - ibuprofen, quantity: 200 mg - tablet, film coated - excipient ingredients: lactose monohydrate; macrogol 400; microcrystalline cellulose; hyprolose; magnesium stearate; colloidal anhydrous silica; maize starch; povidone; sodium lauryl sulfate; hypromellose; titanium dioxide; croscarmellose sodium - for temporary relief of pain & discomfort associated with headache, toothache, dental procedures, backache, muscular pain, period pain, sore throat, tennis elbow, rheumatic pain where inflammation is present and the aches and pains associated with colds and flu. reduces fever. temporary relief of minor pain associated with arthritis.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - paracetamol, quantity: 500 mg - tablet, uncoated - excipient ingredients: magnesium stearate; sodium metabisulfite; pregelatinised maize starch - temporary relief of pain associated with headaches, migraine headache, neuralgia, toothache, sore throat, period pains, rheumatic aches & pain and symptoms of colds and influenza. reduces fever.

Australia - English - Department of Health (Therapeutic Goods Administration)

nia pharmaceuticals pty ltd - 44237 - lubricant, eye - ophthalmic solution moisturizing, lubricating and refreshing particularly suitable for dry eyes and improving the comfort of contact lenses worn. indications: lubricating, moisturizing and refreshing; ideal in case of non-traumatic/non-pathological alterations of the tear film; environmental ocular stress (wind, dust, air conditioning, dry and polluted air, etc.); ocular stress (extended computer use, unfavourable lighting conditions, night driving etc.); indicated in case of extended use of contact lenses; indicated to improve the comfort of the worn contact lenses and reduce fogging; indicated for the prevention of the dirt deposits and the dehydration of the lens; indicated to be used also with contact lenses worn; eliminate the device according to the current legislation

Malta - English - Medicines Authority

mylan ireland limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - pantoprazole - gastro-resistant tablet - pantoprazole 20 mg - drugs for acid related disorders

Israel - English - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 100 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who are homozygous for the f508del mutation in the cftr gene limitations of use the efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation

Israel - English - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 100 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who are homozygous for the f508del mutation in the cftr gene limitations of use the efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation

Israel - English - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation.

Israel - English - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation.